PACB - Pacific Biosciences of California, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.51
-0.03 (-0.40%)
At close: 4:00PM EST

7.51 0.00 (0.00%)
After hours: 7:28PM EST

Stock chart is not supported by your current browser
Previous Close7.54
Open7.55
Bid7.51 x 800
Ask7.55 x 3000
Day's Range7.50 - 7.56
52 Week Range2.02 - 7.84
Volume3,099,770
Avg. Volume3,640,665
Market Cap1.118B
Beta (3Y Monthly)1.21
PE Ratio (TTM)N/A
EPS (TTM)-0.73
Earnings DateJan 30, 2019 - Feb 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.42
Trade prices are not sourced from all markets
  • Here's Why You Should Invest in Illumina (ILMN) Stock Now
    Zacks3 days ago

    Here's Why You Should Invest in Illumina (ILMN) Stock Now

    llumina (ILMN) set to take over peer in a $1.2-billion deal, which will strengthen its position in the genomics market.

  • Pacific Biosciences Offers Insights on Aedes aegypti Genome
    Zacks4 days ago

    Pacific Biosciences Offers Insights on Aedes aegypti Genome

    Pacific Biosciences (PACB) uses its flagship Single Molecule, Real-Time technology to sequence the highest quality genome assembly for the Aedes aegypti mosquito.

  • Is This the Real Reason Illumina Acquired Pacific Biosciences?
    Motley Fool5 days ago

    Is This the Real Reason Illumina Acquired Pacific Biosciences?

    The $1.2 billion acquisition will combine the two leading DNA sequencing technology platforms, but the battle for the future of DNA sequencing is just getting started.

  • GlobeNewswire5 days ago

    PacBio’s SMRT Sequencing Provides Unprecedented Insight into Genome of Disease-causing Mosquito

    Pacific Biosciences of California Inc., (PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that an international team of scientists have published the highest quality genome assembly to date of the Aedes aegypti mosquito genome using its Single Molecule, Real-Time (SMRT®) technology. “The high-quality genome assembly and annotation described here will enable major advances in mosquito biology and has already allowed us to carry out a number of experiments that were previously impossible,” the authors write.

  • ACCESSWIRE8 days ago

    Pacific Biosciences Agrees to be Acquired in an All Cash Transaction, Analysts Review

    NEW YORK, NY / ACCESSWIRE / November 12, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Pacific Biosciences of California, Inc. (PACB), a company that offers sequencing systems to help scientists resolve genetically complex problems. PacBio® sequencing systems, including consumables and software, provide a simple and fast end-to-end workflow for SMRT sequencing. On November 1, 2018, the Company announced they had signed an agreement for Illumina to acquire Pacific Biosciences in an all-cash transaction.

  • Motley Fool11 days ago

    Why Alkermes' Depression Drug Stumbled, and How Illumina Plans to Profit From M&A

    Here's what derailed the drug, and why Illumina is paying $1.2 billion to acquire Pacific Biosciences.

  • Pacific Biosciences (PACB) Reports Q3 Loss, Revenues Fall Y/Y
    Zacks12 days ago

    Pacific Biosciences (PACB) Reports Q3 Loss, Revenues Fall Y/Y

    Pacific Biosciences (PACB) is getting acquired by Illumina (ILMN) by mid-2019.

  • Illumina (ILMN) Inks $1.2B Deal to Buy Pacific Biosciences
    Zacks12 days ago

    Illumina (ILMN) Inks $1.2B Deal to Buy Pacific Biosciences

    Illumina (ILMN) taking out on its peer, in the $1.2-billion acquisition deal, will further strengthen the position of the former in the genomics market.

  • GlobeNewswire13 days ago

    Consolidated Research: 2018 Summary Expectations for Pacific Biosciences of California, NXP Semiconductors N.V., Consolidated Communications, Alexander & Baldwin, Willdan Group, and OneMain — Fundamental Analysis, Key Performance Indications

    NEW YORK, Nov. 07, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE13 days ago

    Big Biotech May Be After These Technologies

    HENDERSON, NV / ACCESSWIRE / November 6, 2018 / Big biotech stock buybacks "have destroyed more than $12 billion in value, and generated no positive return in total, at least as a portfolio investment," ...

  • Pacific Biosciences of California Rose 67.63% on November 2
    Market Realist15 days ago

    Pacific Biosciences of California Rose 67.63% on November 2

    On November 2, Pacific Biosciences of California (PACB) closed at $7.56, which was 67.63% higher than its previous closing price. On November 1, Illumina (ILMN) released a press release announcing the acquisition of Pacific Biosciences of California for a total consideration of $1.2 billion. According to the press release, Illumina expects to close the deal by mid-2019. The acquisition is expected to strengthen Illumina’s position in the genome sequencing market.

  • Here's Why Illimuna Just Bought Its Biggest Competitor
    Motley Fool16 days ago

    Here's Why Illimuna Just Bought Its Biggest Competitor

    Illumina surprised investors this week by announcing it's buying Pacific Biosciences. Here's how the deal could move the needle for investors.

  • Associated Press17 days ago

    Apple and Kraft Heinz drop while Starbucks and Symantec rise

    Stocks that moved substantially or traded heavily on Friday: Apple Inc., down $14.74 to $207.48 The company's revenue forecast disappointed Wall Street and it said it will stop reporting quarterly iPhone ...

  • Why Newell Brands, VeriSign, and Pacific Biosciences of California Jumped Today
    Motley Fool17 days ago

    Why Newell Brands, VeriSign, and Pacific Biosciences of California Jumped Today

    Find out which of these stocks got a buyout bid.

  • Why Pacific Biosciences of California Stock Is Skyrocketing Today
    Motley Fool17 days ago

    Why Pacific Biosciences of California Stock Is Skyrocketing Today

    A $1.2 billion acquisition of the gene-sequencing company sends its shares into orbit.

  • ACCESSWIRE17 days ago

    Surge In Healthcare Growth Sees Rally In These 3 Stocks On Friday

    CORAL GABLES, FL / ACCESSWIRE / November 2, 2018 / Over the last few days, prices of the iShares Nasdaq Biotech ETF (IBB) as well as the SPDR Healthcare ETF (XLV) have recovered from previous lows this week. Premier Health Group, Inc. (PHGRF)(PHGI.CN) saw its shares trade higher on Thursday. Shares of Premier Health Group, Inc. (PHGRF)(PHGI.CN) have begun to trade on the OTC Markets Group Inc.'s OTCQB Venture Market in the United States, under the symbol PHGRF in late October, and are now Depository Trust Company eligible, effective Oct. 22, 2018.

  • Benzinga18 days ago

    Illumina Buys Rival Pacific Biosciences In $1.2B Deal

    Shares of Pacific Biosciences of California (NASDAQ: PACB ), a developer of systems for gene sequencing, are soaring to a two-year high in pre-market trading. What Happened Pacific Biosciences announced ...

  • Benzinga18 days ago

    The Daily Biotech Pulse: Illumina Snaps Up Pacific Bioscience, Thumbs Down For Alkermes Depressive Disorder Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 1) Gritstone Oncology Inc (NASDAQ: GRTS ) Repligen Corporation ...

  • Pacific Biosciences of California (PACB) Reports Q3 Loss, Lags Revenue Estimates
    Zacks18 days ago

    Pacific Biosciences of California (PACB) Reports Q3 Loss, Lags Revenue Estimates

    Pacific Biosciences (PACB) delivered earnings and revenue surprises of -18.75% and -17.29%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Pacific Biosciences of California Reports a Dismal Quarter -- and a Delightful Acquisition
    Motley Fool18 days ago

    Pacific Biosciences of California Reports a Dismal Quarter -- and a Delightful Acquisition

    A pending buyout by Illumina overshadows the gene-sequencing company's third-quarter performance.

  • Associated Press18 days ago

    Pacific Biosciences: 3Q Earnings Snapshot

    On a per-share basis, the Menlo Park, California-based company said it had a loss of 19 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...

  • Illumina Inc. to buy Menlo Park-based biotech firm for $1.2 billion
    American City Business Journals18 days ago

    Illumina Inc. to buy Menlo Park-based biotech firm for $1.2 billion

    Illumina Inc. said it plans to purchase Menlo Park-based Pacific Biosciences of California Inc. for approximately $1.2 billion in a move to accelerate its scientific discovery and long-read sequencing, the company said Thursday. The all-cash transaction was set at a price of $8 per Pacific Biosciences share, with the price representing a 71 percent premium to Pacific Biosciences’ 30 trading day price, according to a statement. Illumina hopes to use the acquisition to integrate workflows and technologies "to help researchers advance their discoveries faster and clinicians offer new tests economically." “PacBio’s unmatched accuracy mirrors that of Illumina’s in short-read sequencing,” said Francis deSouza, Illumina’s president and CEO, in the statement.

  • Reuters18 days ago

    Illumina to buy rival Pacific Biosciences in $1.2 bln deal

    Gene sequencing company Illumina Inc said http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20181101:nBw18KCRQa on Thursday it plans to buy smaller rival Pacific Biosciences of California Inc in an all-cash deal valued at $1.2 billion, expanding its capabilities as the market grows. Illumina's offer of $8 per Pacific share represents a premium of about 77 percent to Pacific's Thursday close. Illumina is a major player in the nascent gene sequencing space and last year unveiled its NovaSeq sequencing platform, which is designed to deliver faster and cheaper gene sequencing over existing models.

  • Reuters18 days ago

    Gene sequencing company Illumina to buy Pacific Biosciences in $1.2 billion deal

    (Reuters) - Gene sequencing company Illumina Inc (ILMN.O) said http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20181101:nBw18KCRQa on Thursday it plans to buy Pacific ...

  • MarketWatch18 days ago

    Illumina to acquire Pacific Biosciences for $1.2 billion in cash

    Illumina Inc. said late Thursday that it plans to acquire Pacific Biosciences of California Inc. for $1.2 billion. Illumina stock was down less than 1% in after hours trading. Illumina said it will pay $8 per share in an all-cash deal. "[Pacific Biosciences] unmatched accuracy mirrors that of Illumina's in short-read sequencing," Illumina Chief Executive Francis deSouza said. "Combining the two technologies positions us to reach more applications, accelerate the pace of genomic discovery and bolster our innovation engine which has been a hallmark of Illumina since our inception." Goldman Sachs is serving as a financial advisor for the transaction. Illumina will hold a conference call at 5 p.m. Eastern time to discuss the transaction. Illumina stock is up 43% this year as the S&P 500 index has gained 2.5%.